Population pharmacokinetics and optimized dosing of piperacillin-tazobactam in hematological patients with febrile neutropenia
Por:
Laporte-Amargos, J, Ulldemolins, M, Hernández-Mitre, MP, Roberts, JA, Rigo-Bonnin, R, Carmona-Torre, F, Huguet, M, Puerta-Alcalde, P, Arnan, M, Del Pozo, JL, Torrent, A, García-Vidal, C, Sureda, A, Bergas, A, Sastre-Escolà, E, Carratalà, J and Gudiol, C
Publicada:
1 nov 2025
Ahead of Print:
1 nov 2025
Resumen:
Hematological patients with febrile neutropenia receiving piperacillin-tazobactam may experience pharmacokinetic alterations that compromise drug exposure. We aimed to characterize the population pharmacokinetics of piperacillin in plasma and provide optimized dosing recommendations for this patient population. A population pharmacokinetic analysis was conducted in patients who received piperacillin-tazobactam as part of the BEATLE study, which compared the efficacy, safety, and pharmacokinetic/pharmacodynamic target attainment of beta-lactams administered in extended infusion versus short 30 min infusion in adult hematological patients with febrile neutropenia. Monte Carlo simulations were performed to evaluate, for each dosing regimen, the probability of attaining (i) an efficacy target of unbound piperacillin concentrations above the minimum inhibitory concentration (MIC) of the bacteria for the entire dosing interval (100% & fnof;T->MIC), and (ii) a toxicity threshold of >= 160 mg/L. A total of 44 patients and 221 plasma concentrations were included. A one-compartment model best described piperacillin plasma pharmacokinetics, with Cockcroft-Gault creatinine clearance (CrCL) significantly influencing drug clearance. Dosing simulations showed that extended and continuous infusions were superior to short 30 min infusions in the attainment of 100% & fnof;T->MIC, even for bacteria with low to intermediate MIC (<= 2-4 mg/L). In patients with higher CrCL (>90 mL/min) or infections caused by less susceptible Gram-negative bacilli (MIC: 8-16 mg/L), only continuous infusions of 12-16 g/day were likely to achieve 100% & fnof;T->MIC. These findings support the use of extended or continuous infusions of piperacillin in the initial management of patients with febrile neutropenia, particularly in patients with higher CrCL or when infections caused by less susceptible pathogens, such as Pseudomonas aeruginosa, are suspected.
Filiaciones:
Laporte-Amargos, J:
Bellvitge Univ Hosp, Dept Infect Dis, Lhospitalet de Llobregat 08907, Barcelona, Spain
Univ Barcelona, Sch Med, Barcelona, Spain
Ulldemolins, M:
Bellvitge Univ Hosp, Dept Infect Dis, Lhospitalet de Llobregat 08907, Barcelona, Spain
Univ Queensland, Fac Hlth Med & Behav Sci HMBS, UQ Ctr Clin Res, Brisbane, Qld, Australia
Hernández-Mitre, MP:
Univ Queensland, Fac Hlth Med & Behav Sci HMBS, UQ Ctr Clin Res, Brisbane, Qld, Australia
Roberts, JA:
Univ Queensland, Fac Hlth Med & Behav Sci HMBS, UQ Ctr Clin Res, Brisbane, Qld, Australia
Metro North Hlth, Herston Infect Dis Inst HeIDI, Brisbane, Australia
Royal Brisbane & Womens Hosp, Dept Pharm, Brisbane, Australia
Royal Brisbane & Womens Hosp, Dept Intens Care Med, Brisbane, Australia
Univ Montpellier, Nimes Univ Hosp, UR UM 103, Div Anesthesia Crit Care & Emergency & Pain Med, Nimes, France
Rigo-Bonnin, R:
Bellvitge Univ Hosp, Bellvitge Biomed Res Inst IDIBELL, Dept Clin Lab, Lhospitalet De Llobregat, Barcelona, Spain
Carmona-Torre, F:
Clin Univ Navarra, Navarra Inst Hlth Res IdiSNA, Dept Infect Dis, Pamplona, Navarra, Spain
Huguet, M:
Hosp Germans Trias i Pujol, Josep Carreras Leukaemia Res Inst, Inst Catala Oncol Badalona, Dept Clin Haematol, Badalona, Spain
:
Hosp Clin Barcelona, Inst Invest Biomed August Pi Sunyer IDIBAPS i, Infect Dis Dept, Barcelona, Spain
Arnan, M:
Univ Barcelona, Sch Med, Barcelona, Spain
IDIBELL, Inst Catala Oncol Hosp, Dept Clin Haematol, Lhospitalet Llobregat, Barcelona, Spain
Del Pozo, JL:
Clin Univ Navarra, Navarra Inst Hlth Res IdiSNA, Dept Infect Dis, Pamplona, Navarra, Spain
Torrent, A:
Hosp Germans Trias i Pujol, Josep Carreras Leukaemia Res Inst, Inst Catala Oncol Badalona, Dept Clin Haematol, Badalona, Spain
García-Vidal, C:
Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Infecciosas CIB, Madrid, Spain
Sureda, A:
IDIBELL, Inst Catala Oncol Hosp, Dept Clin Haematol, Lhospitalet Llobregat, Barcelona, Spain
Bergas, A:
Bellvitge Univ Hosp, Dept Infect Dis, Lhospitalet de Llobregat 08907, Barcelona, Spain
Sastre-Escolà, E:
Bellvitge Univ Hosp, Dept Infect Dis, Lhospitalet de Llobregat 08907, Barcelona, Spain
Univ Barcelona, Sch Med, Barcelona, Spain
Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Infecciosas CIB, Madrid, Spain
Carratalà, J:
Bellvitge Univ Hosp, Dept Infect Dis, Lhospitalet de Llobregat 08907, Barcelona, Spain
Univ Barcelona, Sch Med, Barcelona, Spain
Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Infecciosas CIB, Madrid, Spain
Bellvitge Biomed Res Inst IDIBELL, Lhospitalet De Llobregat, Barcelona, Spain
Gudiol, C:
Bellvitge Univ Hosp, Dept Infect Dis, Lhospitalet de Llobregat 08907, Barcelona, Spain
Univ Barcelona, Sch Med, Barcelona, Spain
Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Infecciosas CIB, Madrid, Spain
Bellvitge Biomed Res Inst IDIBELL, Lhospitalet De Llobregat, Barcelona, Spain
Inst Catala Oncol, Lhospitalet Llobregat, Barcelona, Spain
Green Submitted, gold
|